Accredited Investors Inc. Buys Shares of 12,845 Revance Therapeutics, Inc. (NASDAQ:RVNC)

Accredited Investors Inc. purchased a new stake in shares of Revance Therapeutics, Inc. (NASDAQ:RVNC) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 12,845 shares of the biopharmaceutical company’s stock, valued at approximately $67,000.

A number of other institutional investors have also made changes to their positions in RVNC. Certuity LLC acquired a new stake in Revance Therapeutics in the 2nd quarter valued at approximately $26,000. Creative Planning acquired a new stake in Revance Therapeutics during the 3rd quarter worth approximately $56,000. Vanguard Personalized Indexing Management LLC purchased a new position in Revance Therapeutics in the 2nd quarter valued at approximately $33,000. Hsbc Holdings PLC acquired a new position in shares of Revance Therapeutics in the second quarter worth $38,000. Finally, Nisa Investment Advisors LLC increased its position in shares of Revance Therapeutics by 2,167.5% during the second quarter. Nisa Investment Advisors LLC now owns 18,911 shares of the biopharmaceutical company’s stock worth $49,000 after acquiring an additional 18,077 shares during the period. 97.70% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

RVNC has been the topic of several recent research reports. Stifel Nicolaus cut their price target on Revance Therapeutics from $24.00 to $20.00 and set a “buy” rating on the stock in a report on Friday, August 9th. Barclays reaffirmed an “equal weight” rating and issued a $7.00 target price (down previously from $10.00) on shares of Revance Therapeutics in a report on Friday, September 13th. Piper Sandler cut shares of Revance Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, August 12th. William Blair restated a “market perform” rating on shares of Revance Therapeutics in a report on Monday, August 12th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Revance Therapeutics in a research report on Friday, November 8th. Nine investment analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to MarketBeat, Revance Therapeutics has a consensus rating of “Hold” and an average price target of $9.66.

Revance Therapeutics Trading Down 3.2 %

Shares of NASDAQ:RVNC opened at $4.17 on Monday. The firm has a 50 day simple moving average of $5.41 and a 200-day simple moving average of $4.44. The company has a market capitalization of $437.44 million, a PE ratio of -2.16 and a beta of 0.95. Revance Therapeutics, Inc. has a twelve month low of $2.30 and a twelve month high of $9.74.

Revance Therapeutics (NASDAQ:RVNC) last announced its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.02). The company had revenue of $59.88 million for the quarter, compared to analysts’ expectations of $67.73 million. As a group, equities research analysts predict that Revance Therapeutics, Inc. will post -1.54 EPS for the current fiscal year.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.